Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)

NCT02024789 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02024789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02024789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
May 5, 2014
Completion date
May 4, 2016
Enrollment
173 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome